课题基金 / 基金详情

HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS

HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
多发性硬化症急性加重中的 HU23F2G
批准号：
6121136
负责人：
Jerry Saul Wolinsky
金额：
$1.51万
依托单位：
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6121136
关键词：
clinical research drug screening /evaluation hormone therapy human subject human therapy evaluation immunotherapy methylprednisolone monoclonal antibody multiple sclerosis

项目摘要

项目成果

Jerry Saul Wolinsky的其他基金

相关文献

中文摘要
翻译
该研究旨在评估静脉注射Hu23F2G对多发性硬化症（MS）急性加重患者的疗效和安全性，并与安慰剂和皮质类固醇治疗进行比较。Hu23F2G是一种人源化抗cd18单克隆抗体，在非人类灵长类动物ms实验模型中有效。这是一项2期研究，患者将随机接受安慰剂、甲基泼尼isoline或Hu23F2G治疗3天，剂量为1或2 mg/kg。治疗后随访1年。这次试验的结果正在分析中。
英文摘要
The study was designed to evaluate the efficacy & safety of Hu23F2G administered intravenously to patients with acute exacerbations of multiple sclerosis (MS) as compared to placebo and corticosteroid treatment. Hu23F2G is a humanized anti-CD18 monoclonal antibody which has been effective in a non-human primate experimental model of MS. This was a Phase 2 study in which patients will be randomized to treatment for 3 days with placebo, methylprednisoline, or Hu23F2G at 1 or 2 mg/kg. Subjects were be followed for 1 year after treatment. The results of this trial are under analysis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
AVONEX IN TREATMENT OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY
SAFETY OF TIZANIDINE IN PATIENTS WITH MS--OPEN LABEL EVALUATION